2020-02-14

2019 year-end financial report: Sites opened for recruitment to the pivotal Phase III study SPARKLE

Ascelia Pharma AB (publ) (ticker: ACE) today published its year-end report for the period July 2019 – December 2019, which is now available on the company’s website (the financial year will going forward follow the calendar year): https://www.ascelia.com/tag/reports-presentations/
2020-02-11

Ascelia Pharma wins the award for Best Life Science company in Malmö

Ascelia Pharma AB (publ) (ticker: ACE) was yesterday evening awarded the price for best Life Science company in Malmö at the city’s prestigious annual corporate awards (Malmö Näringslivsgala). The price award follows Ascelia Pharma’s work on developing novel drug candidates that fill a distinct unmet medical need.
2020-01-13

Five sites now opened in the pivotal Phase III clinical study SPARKLE for lead drug candidate Mangoral

Ascelia Pharma AB (publ) (ticker: ACE) today informed that there are a number of sites now open for enrolment of patients in both the US and Europe in the global pivotal Phase III clinical study SPARKLE with Mangoral[®]. Enrolment of the first patient is expected shortly.